Merck Reports Q1 GAAP Net Loss Driven by $9.0B Cidara Acquisition Charge; Updates on Key Products & Pipeline

summarizeSummary

Merck reported a Q1 GAAP net loss of $4.24 billion, or $1.72 per share, primarily due to $9.0 billion in R&D charges from the Cidara acquisition and an expected $5.8 billion charge from the Terns acquisition. Key product sales were mixed, with strong growth in oncology and cardiometabolic areas, while older products faced declines. The company also announced a proposed settlement for Gardasil litigation and secured a $6.0 billion loan for the Terns acquisition.

check_boxKey Events

• Q1 GAAP Net Loss Reported

  Merck reported a Q1 2026 GAAP net loss of $4.24 billion, or $1.72 per share, a significant shift from a $5.08 billion net income in Q1 2025. This contrasts with the previously announced Q1 adjusted loss per share of $1.28.

• Major R&D Charges from Acquisitions

  The net loss was primarily driven by a $9.0 billion R&D charge related to the January 2026 acquisition of Cidara Therapeutics. Additionally, a $5.8 billion R&D charge is anticipated from the definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, expected to close in May 2026.

• Mixed Product Sales Performance

  Combined global sales of Keytruda/Keytruda Qlex grew 12% to $8.03 billion, and Winrevair sales rose 88% to $525 million. However, Gardasil/Gardasil 9 sales declined 19%, and Januvia/Janumet sales fell 28% due to competition and upcoming loss of U.S. market exclusivity.

• Gardasil Litigation Settlement

  Merck entered into a proposed agreement in October 2025 to substantially resolve the Gardasil product liability litigation for a payment deemed 'not material' and considerably less than anticipated defense costs.

auto_awesomeAnalysis

Merck's Q1 2026 financial results show a significant GAAP net loss, primarily due to substantial R&D charges from strategic acquisitions. While the adjusted earnings per share were largely pre-announced in a recent 8-K, this 10-Q provides the full GAAP financial details and the underlying drivers. The $9.0 billion charge for the Cidara Therapeutics acquisition and the anticipated $5.8 billion charge for the Terns Pharmaceuticals acquisition highlight Merck's aggressive pipeline expansion efforts, which are long-term strategic investments despite the immediate negative impact on reported earnings. The mixed performance of key products, with strong growth in oncology (Keytruda, Welireg) and cardiometabolic (Winrevair) offset by declines in vaccines (Gardasil) and diabetes (Januvia/Janumet) due to competition and patent expirations, indicates a dynamic portfolio shift. The proposed settlement of the Gardasil litigation is a positive development, mitigating a significant legal overhang. Investors should monitor the integration of new acquisitions, the impact of upcoming patent expirations, and the realization of cost savings from restructuring programs.